Kedalion Therapeutics

About:

Kedalion Therapeutics is a biotechnology company that develops and commercializes transformative topical ophthalmic therapies.

Website: https://kedalionthera.com/

Top Investors: Novartis Venture Fund, Lagunita BioSciences

Description:

Kedalion Therapeutics is a biotechnology company that develops and commercializes transformative topical ophthalmic therapies for both new and existing indications. When compared to standard eye drops, Kedalion's proprietary AcuStream platform technology delivers topical drugs to the eye in a precise and accurate manner, enabling comparable effects with up to an 80% reduction in dose. AcuStream is a novel, digitally connected, electromechanical topical ocular delivery device that aims to fill a potential unmet need for a convenient, user-friendly device that reliably, accurately, and comfortably delivers topical ocular therapy with increased efficiency and patient comfort.

Total Funding Amount:

$5M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Menlo Park, California, United States

Founded Date:

2015-01-01

Contact Email:

info(AT)kedalionthera.com

Founders:

Ehud Ivri, Mark Blumenkranz

Number of Employees:

1-10

Last Funding Date:

2021-11-15

IPO Status:

Private

Industries:

© 2025 bioDAO.ai